Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 10/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.57 |
| ▸ | HTR6 | P50406 | 3/20 | 0.57 |
| ▸ | HTR1A | P08908 | 5/20 | 0.56 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | HTR7 | P34969 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6593331 | 0.92 | DRD2 (0.60) | DRD2KCNH2HTR1ASLC6A4HTR7 | |
| SCHEMBL6582722 | 0.91 | KCNH2 (0.67) | DRD2KCNH2HTR6HTR1ASLC6A4 | |
| SCHEMBL6589455 | 0.90 | HTR1A (0.64) | DRD2KCNH2HTR1ASLC6A4HTR7 | |
| SCHEMBL6582451 | 0.88 | KCNH2 (0.64) | DRD2KCNH2HTR6HTR1ASLC6A4 | |
| SCHEMBL6593130 | 0.88 | DRD2 (0.67) | DRD2KCNH2HTR1ASLC6A4HTR7 | |
| SCHEMBL6580844 | 0.88 | KCNH2 (0.64) | DRD2KCNH2HTR6HTR1ASLC6A4 | |
| SCHEMBL6592113 | 0.87 | DRD2 (0.59) | DRD2KCNH2HTR1ASLC6A4HTR7 | |
| SCHEMBL6589609 | 0.87 | DRD2 (0.63) | DRD2KCNH2HTR6HTR1ASLC6A4 | |
| SCHEMBL6582940 | 0.85 | KCNH2 (0.57) | DRD2KCNH2HTR6HTR1ASLC6A4 | |
| SCHEMBL6582650 | 0.85 | KCNH2 (0.53) | DRD2KCNH2HTR6HTR1ASLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1246815-B1 | PHENYLPIPERAZINYL DERIVATIVES | LUNDBECK & CO AS H (DK) | 2004-03-17 | — | — | EP | disclosed |
| US-20030083336-A1 | Phenylpiperazinyl derivatives | H. LUNDBECK A/S (DK) | 2003-05-01 | — | — | US | disclosed |
| US-20030040639-A1 | Method for the preparation of substituted benzene derivatives | H. LUNDBECK A/S (DK) | 2003-02-27 | — | — | US | disclosed |
| EP-1246815-A1 | PHENYLPIPERAZINYL DERIVATIVES | H. Lundbeck A/S (DK) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001049677-A1 | PHENYLPIPERAZINYL DERIVATIVES | H. LUNDBECK A/S (DK) | 2001-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030083336-A1 | Phenylpiperazinyl derivatives | DRD4, DRD2, DRD3 | DRD2 2/4885KCNH2 341/4885HTR6 72/4885 |
| US-20030040639-A1 | Method for the preparation of substituted benzene derivatives | SCLY, CBR3, TST | DRD2 1490/4885KCNH2 1646/4885HTR6 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.